Table 4.
Baseline PTSD Checklist and Outcomes (All Patients) According to Drug Combination Received, National Cohort of US Department of Veterans Affairs Patients With Posttraumatic Stress Disorder and Hepatitis C Virus, United States, October 1999 to September 2019
| GLE/PIB(n = 54) | LDV/SOF(n = 145) | SOF/VEL(n = 54) | GLE/PIB Versus LDV/SOF | GLE/PIB Versus SOF/VEL | SOF/VEL Versus LDV/SOF | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Analysis | Mean (SD) | % | No. | Mean (SD) | % | No. | Mean (SD) | % | No. | MD | OR | 95% CI | MD | OR | 95% CI | MD | OR | 95% CI |
| Baseline PCL | ||||||||||||||||||
| Unweighted | 48.4 (16.3) | 49.1 (15.9) | 50.9 (16.1) | 0.67 | −4.39, 5.73 | 2.47 | −3.63, 8.57 | −1.80 | −6.81, 3.21 | |||||||||
| IPTW | 44.1 (20.8) | 47.2 (49.1) | 48.0 (32.2) | 3.10 | −2.64, 8.84 | 3.89 | −2.67, 10.46 | −0.80 | −9.52, 7.92 | |||||||||
| Change in PCL | ||||||||||||||||||
| Unweighted | −12.9 (14.3) | −3.1 (14.1) | −9.2 (14.7) | 9.79 | 5.33, 14.25 | 3.78 | −1.68, 9.25 | 6.01 | 1.47, 10.54 | |||||||||
| IPTW | −14.9 (33.2) | −7.5 (66.8) | −10.5 (41.9) | 7.34 | 1.05, 13.63 | 4.39 | −2.43, 11.21 | 2.95 | −6.33, 12.23 | |||||||||
| Clinically meaningful improvement | ||||||||||||||||||
| Unweighted | 40.7 | 22 | 17.9 | 26 | 35.2 | 19 | 2.27 | 1.42, 3.65 | 1.16 | 0.71, 1.88 | 1.97 | 1.18, 3.28 | ||||||
| IPTW | 43.6 | 22 | 26.3 | 26 | 30.3 | 19 | 2.17 | 0.93, 5.06 | 1.41 | 0.58, 3.42 | 1.54 | 0.45, 5.24 | ||||||
Abbreviations: CI, confidence interval; GLE/PIB, glecaprevir/pibrentasvir; IPTW, inverse propensity of treatment weighting; LDV/SOF, ledipasvir/sofosbuvir; MD, mean difference; OR, odds ratio; PCL, PTSD Checklist; PTSD, posttraumatic stress disorder; SD, standard deviation; SOF/VEL, sofosbuvir/velpatasvir.